These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 29389947)

  • 1. Whole exome sequencing in neurogenetic odysseys: An effective, cost- and time-saving diagnostic approach.
    Córdoba M; Rodriguez-Quiroga SA; Vega PA; Salinas V; Perez-Maturo J; Amartino H; Vásquez-Dusefante C; Medina N; González-Morón D; Kauffman MA
    PLoS One; 2018; 13(2):e0191228. PubMed ID: 29389947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness.
    Palmer EE; Schofield D; Shrestha R; Kandula T; Macintosh R; Lawson JA; Andrews I; Sampaio H; Johnson AM; Farrar MA; Cardamone M; Mowat D; Elakis G; Lo W; Zhu Y; Ying K; Morris P; Tao J; Dias KR; Buckley M; Dinger ME; Cowley MJ; Roscioli T; Kirk EP; Bye A; Sachdev RK
    Mol Genet Genomic Med; 2018 Mar; 6(2):186-199. PubMed ID: 29314763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cou Cou, flying fish and a whole exome please... lessons learned from genetic testing in Barbados.
    Scantlebury MH; Barrett KT; Jacinto S; Corbin DOC; Kerr M; Khan A
    Pan Afr Med J; 2021; 38():111. PubMed ID: 33912281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of whole-exome sequencing in progressive neurological disorders of children.
    Aaltio J; Hyttinen V; Kortelainen M; Frederix GWJ; Lönnqvist T; Suomalainen A; Isohanni P
    Eur J Paediatr Neurol; 2022 Jan; 36():30-36. PubMed ID: 34852981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of a Targeted Gene Panel for Identification of Genes Associated With Movement Disorders.
    Montaut S; Tranchant C; Drouot N; Rudolf G; Guissart C; Tarabeux J; Stemmelen T; Velt A; Fourrage C; Nitschké P; Gerard B; Mandel JL; Koenig M; Chelly J; Anheim M;
    JAMA Neurol; 2018 Oct; 75(10):1234-1245. PubMed ID: 29913018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.
    Monroe GR; Frederix GW; Savelberg SM; de Vries TI; Duran KJ; van der Smagt JJ; Terhal PA; van Hasselt PM; Kroes HY; Verhoeven-Duif NM; Nijman IJ; Carbo EC; van Gassen KL; Knoers NV; Hövels AM; van Haelst MM; Visser G; van Haaften G
    Genet Med; 2016 Sep; 18(9):949-56. PubMed ID: 26845106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of whole-exome sequencing results in neurogenetic diseases.
    Balasar Ö; Başdemirci M
    J Hum Genet; 2023 Dec; 68(12):797-804. PubMed ID: 37524782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole Exome Sequencing in Pediatric Neurology Patients: Clinical Implications and Estimated Cost Analysis.
    Nolan D; Carlson M
    J Child Neurol; 2016 Jun; 31(7):887-94. PubMed ID: 26863999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience.
    Lazaridis KN; Schahl KA; Cousin MA; Babovic-Vuksanovic D; Riegert-Johnson DL; Gavrilova RH; McAllister TM; Lindor NM; Abraham RS; Ackerman MJ; Pichurin PN; Deyle DR; Gavrilov DK; Hand JL; Klee EW; Stephens MC; Wick MJ; Atkinson EJ; Linden DR; Ferber MJ; Wieben ED; Farrugia G;
    Mayo Clin Proc; 2016 Mar; 91(3):297-307. PubMed ID: 26944241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions.
    Tan TY; Dillon OJ; Stark Z; Schofield D; Alam K; Shrestha R; Chong B; Phelan D; Brett GR; Creed E; Jarmolowicz A; Yap P; Walsh M; Downie L; Amor DJ; Savarirayan R; McGillivray G; Yeung A; Peters H; Robertson SJ; Robinson AJ; Macciocca I; Sadedin S; Bell K; Oshlack A; Georgeson P; Thorne N; Gaff C; White SM
    JAMA Pediatr; 2017 Sep; 171(9):855-862. PubMed ID: 28759686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency.
    Platt CD; Zaman F; Bainter W; Stafstrom K; Almutairi A; Reigle M; Weeks S; Geha RS; Chou J;
    J Allergy Clin Immunol; 2021 Feb; 147(2):723-726. PubMed ID: 32888943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology.
    Vissers LELM; van Nimwegen KJM; Schieving JH; Kamsteeg EJ; Kleefstra T; Yntema HG; Pfundt R; van der Wilt GJ; Krabbenborg L; Brunner HG; van der Burg S; Grutters J; Veltman JA; Willemsen MAAP
    Genet Med; 2017 Sep; 19(9):1055-1063. PubMed ID: 28333917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consecutive medical exome analysis at a tertiary center: Diagnostic and health-economic outcomes.
    Kosaki R; Kubota M; Uehara T; Suzuki H; Takenouchi T; Kosaki K
    Am J Med Genet A; 2020 Jul; 182(7):1601-1607. PubMed ID: 32369273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation.
    Hayeems RZ; Bernier F; Boycott KM; Hartley T; Michaels-Igbokwe C; Marshall DA
    BMJ Open; 2022 Oct; 12(10):e061468. PubMed ID: 36216418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of whole-exome sequencing and copy number variation sequencing enables the diagnosis of rare neurological disorders.
    Jiao Q; Sun H; Zhang H; Wang R; Li S; Sun D; Yang XA; Jin Y
    Clin Genet; 2019 Aug; 96(2):140-150. PubMed ID: 30945278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proband-only medical exome sequencing as a cost-effective first-tier genetic diagnostic test for patients without prior molecular tests and clinical diagnosis in a developing country: the China experience.
    Hu X; Li N; Xu Y; Li G; Yu T; Yao RE; Fu L; Wang J; Yin L; Yin Y; Wang Y; Jin X; Wang X; Wang J; Shen Y
    Genet Med; 2018 Sep; 20(9):1045-1053. PubMed ID: 29095814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disorders.
    Nurchis MC; Radio FC; Salmasi L; Heidar Alizadeh A; Raspolini GM; Altamura G; Tartaglia M; Dallapiccola B; Damiani G
    Eur J Health Econ; 2024 Aug; 25(6):999-1011. PubMed ID: 37975990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Yield and Economic Implications of Whole-Exome Sequencing for ASD Diagnosis in Israel.
    Tal-Ben Ishay R; Shil A; Solomon S; Sadigurschi N; Abu-Kaf H; Meiri G; Flusser H; Michaelovski A; Dinstein I; Golan H; Davidovitch N; Menashe I
    Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal trends and yield of clinical diagnostic genetic testing in adult neurology.
    Guo MH; Bardakjian TM; Brzozowski MR; Scherer SS; Quinn C; Elman L; Orthmann-Murphy J; Tropea TF; Ellis CA; Gonzalez-Alegre P
    Am J Med Genet A; 2021 Oct; 185(10):2922-2928. PubMed ID: 34075706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness.
    Stark Z; Schofield D; Martyn M; Rynehart L; Shrestha R; Alam K; Lunke S; Tan TY; Gaff CL; White SM
    Genet Med; 2019 Jan; 21(1):173-180. PubMed ID: 29765138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.